Kashyap Patel, MD: Misconceptions About Biosimilars

Transcript

That's very interesting question, because the prescribers are still not aware of the rigorous pathway—there’s something called the totality of the evidence that’s undergone in terms of evaluating the molecule. Many prescribers even now think that biosimilars and generics are the same. There’s a significant difference and a significant cost difference in developing a biosimilar, so there are a lot of misconceptions prevailing among my colleagues as well as many prescribers. As a chairman of the biosimilars committee at the [Community Oncology Alliance, COA], we’re trying to help address the knowledge gap and the needs assessment in the biosimilars market.